As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year characterized by regulatory uncertainty and legal skirmishes, the company’s stock staged a breathtaking 50%+ rally in the first two weeks of March. This [...]
The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.
Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa. However, the larger word is uncertainty. Specifically, how long will the conflict continue, and what will normal look like for energy prices when it’s over?
As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from a controversial provider of compounded GLP-1 medications to a cornerstone of the global pharmaceutical distribution network. The catalyst for this transformation was [...]
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers Health (NYSE: HIMS), a company that has navigated a volatile journey from a telehealth disruptor to a central pillar of the modern [...]
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant Novo Nordisk (NYSE: NVO). The deal, which effectively ends a high-stakes patent dispute, has propelled HIMS shares to record highs, closing the
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.
Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i...
As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a "wellness-lite" platform for hair loss and erectile dysfunction, Hims & Hers has evolved into a diversified healthcare titan. Today, the company finds itself [...]
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.
